Having demonstrated the anti-colitic effect of M(IL4)s and the preservation of gut barrier function, the current study yielded no data to suggest that M(IL4) therapy would exaggerate or leave an individual more vulnerable to concomitant infection, CRC or airways inflammation. This evidence concerns the gene IL4 and infection.